Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology is a development-stage life sciences company focused on revolutionizing proteomics. Their Nautilus Platform aims to provide an end-to-end solution for quantifying and unlocking the complexity of the proteome, potentially transforming drug discovery and personalized medicine.
Company Overview
Nautilus Biotechnology is pioneering a novel proteomics platform, the Nautilus Platform, poised to revolutionize drug discovery and personalized medicine by offering unprecedented proteome quantification. Founded in 2016, Nautilus is strategically positioned to capitalize on the growing demand for comprehensive proteomics solutions, offering a potential paradigm shift in biological research.
Investment Thesis
Investing in Nautilus Biotechnology presents a compelling opportunity to capitalize on the rapidly growing proteomics market. The Nautilus Platform, with its potential to revolutionize protein quantification, positions the company for significant growth as it transitions from development to commercialization. Key value drivers include successful platform validation, strategic partnerships with pharmaceutical companies and research institutions, and expansion of the platform's applications beyond drug discovery. With a market capitalization of $0.26 billion and a beta of 1.36, Nautilus offers high-growth potential, albeit with inherent risks associated with development-stage companies. The absence of a dividend reflects the company's focus on reinvesting capital into R&D and commercialization efforts. Successful execution of their platform launch could lead to substantial returns for investors.
Key Highlights
- Nautilus Biotechnology is a development stage company focused on proteomics, a rapidly growing field in life sciences.
- The Nautilus Platform is designed as an end-to-end solution, including instruments, consumables, and software analysis, offering a comprehensive approach to proteomics.
- The company was founded in 2016 and is headquartered in Seattle, Washington, a hub for biotechnology innovation.
- Nautilus has a market capitalization of $0.26 billion, reflecting investor interest in its potential.
- The company has 134 employees, indicating a focused and specialized team dedicated to platform development.
Competitors
Strengths
- Novel proteomics platform with potential for high sensitivity and throughput.
- Comprehensive end-to-end solution including instruments, consumables, and software.
- Experienced team of scientists and engineers.
- Strong intellectual property position.
Weaknesses
- Development-stage company with no commercial products.
- High cash burn rate.
- Reliance on successful platform validation and market adoption.
- Limited brand recognition.
Catalysts
- Upcoming: Successful validation of the Nautilus Platform in key research applications.
- Ongoing: Strategic partnerships with pharmaceutical companies and research institutions.
- Upcoming: Publication of peer-reviewed articles demonstrating the platform's capabilities.
- Ongoing: Expansion of the platform's applications beyond drug discovery.
- Upcoming: Commercial launch of the Nautilus Platform.
Risks
- Potential: Failure to successfully validate the Nautilus Platform.
- Ongoing: Competition from established proteomics companies.
- Potential: Technological advancements that could render the Nautilus Platform obsolete.
- Ongoing: High cash burn rate and need for additional financing.
- Potential: Regulatory hurdles for diagnostic applications.
Growth Opportunities
- Expansion into Drug Discovery: Nautilus can leverage its platform to offer drug discovery services to pharmaceutical companies. By providing comprehensive proteomic analysis, Nautilus can help identify novel drug targets and accelerate the development of new therapies. The drug discovery market is a multi-billion dollar industry, and Nautilus's unique platform could capture a significant share. This expansion could begin within the next 2-3 years as the platform gains validation and adoption.
- Partnerships with Research Institutions: Collaborating with leading research institutions will provide Nautilus with access to cutting-edge research and validation of its platform. These partnerships can generate valuable data and publications, enhancing the credibility and market acceptance of the Nautilus Platform. Research funding for proteomics is substantial, and Nautilus can tap into these resources through strategic collaborations. Expect to see partnership announcements within the next year.
- Development of Diagnostic Applications: The Nautilus Platform can be adapted for diagnostic applications, enabling the early detection and monitoring of diseases. By identifying protein biomarkers, Nautilus can develop diagnostic tests for various conditions, including cancer and cardiovascular disease. The diagnostics market is a rapidly growing segment of the healthcare industry, offering significant revenue potential. Development and regulatory approval for diagnostic applications may take 3-5 years.
- Expansion into Personalized Medicine: As personalized medicine gains traction, Nautilus can play a key role in tailoring treatments to individual patients based on their proteomic profiles. By analyzing a patient's proteins, Nautilus can help physicians select the most effective therapies and monitor treatment response. The personalized medicine market is projected to grow significantly in the coming years, driven by advances in genomics and proteomics. This application is a longer-term opportunity, potentially materializing in 5-7 years.
- Geographic Expansion: Nautilus can expand its commercial operations beyond the United States, targeting key markets in Europe and Asia. These regions have a strong research base and a growing demand for proteomics solutions. Establishing a presence in these markets will require strategic partnerships and investments in sales and marketing. International expansion could begin within the next 3-4 years, contingent on successful platform validation and market acceptance in the US.
Opportunities
- Expansion into drug discovery services.
- Partnerships with research institutions and pharmaceutical companies.
- Development of diagnostic applications.
- Geographic expansion into Europe and Asia.
Threats
- Competition from established proteomics companies.
- Technological advancements that could render the Nautilus Platform obsolete.
- Regulatory hurdles for diagnostic applications.
- Economic downturn that could reduce research funding.
Competitive Advantages
- Proprietary Technology: The Nautilus Platform is based on novel and patented technology, creating a barrier to entry for competitors.
- End-to-End Solution: The company offers a comprehensive solution, including instruments, consumables, and software, providing a seamless experience for customers.
- Scalability: The platform is designed to handle large-scale proteomic analysis, enabling researchers to study the proteome with unprecedented depth.
- Expertise: Nautilus has a team of experienced scientists and engineers with expertise in proteomics and related fields.
About
Nautilus Biotechnology, Inc., established in 2016 and headquartered in Seattle, Washington, is a development-stage life sciences company dedicated to creating a groundbreaking platform technology for quantifying and unlocking the complexity of the proteome. Recognizing the limitations of existing proteomics methods, Nautilus embarked on a mission to develop a more comprehensive and accessible solution. The company's core offering is the Nautilus Platform, an end-to-end solution encompassing instruments, consumables, and sophisticated software analysis. This platform is designed to enable researchers to identify and quantify proteins with unprecedented scale and sensitivity, providing deeper insights into biological processes and disease mechanisms. The Nautilus Platform aims to overcome the challenges associated with traditional proteomics approaches, such as limited throughput, high cost, and complex workflows. By integrating innovative technologies and proprietary algorithms, Nautilus seeks to empower scientists to accelerate drug discovery, improve diagnostics, and advance personalized medicine. Currently, Nautilus is focused on the continued development and validation of its platform, working towards commercialization and widespread adoption within the research community. The company believes its technology has the potential to transform the field of proteomics and unlock new frontiers in biological understanding.
What They Do
- Develop a proteomics platform called the Nautilus Platform.
- Create instruments for protein analysis.
- Produce consumables used in the protein analysis process.
- Develop software for analyzing proteomic data.
- Offer an end-to-end solution for quantifying proteins.
- Aim to unlock the complexity of the proteome for research and drug discovery.
- Provide tools for identifying and quantifying proteins with high sensitivity.
Business Model
- Selling instruments for protein analysis to research institutions and pharmaceutical companies.
- Generating recurring revenue through the sale of consumables used with the Nautilus Platform.
- Offering software licenses for proteomic data analysis.
- Potentially offering drug discovery services based on its platform.
Industry Context
Nautilus Biotechnology operates within the dynamic and expanding proteomics market, a segment of the broader life sciences industry focused on the study of proteins. The proteomics market is driven by increasing demand for personalized medicine, drug discovery, and diagnostics. This market is characterized by intense competition, with established players and emerging companies vying for market share. Competitors like ARCT, ASMB, ENTA, FHTX, and HUMA are also developing innovative technologies in related fields. Nautilus aims to differentiate itself through its comprehensive platform and its potential to provide unprecedented proteome quantification. The global proteomics market is projected to reach billions of dollars in the coming years, presenting substantial growth opportunities for companies like Nautilus.
Key Customers
- Pharmaceutical companies involved in drug discovery and development.
- Biotechnology companies focused on protein-based research.
- Academic research institutions conducting proteomics studies.
- Clinical research organizations (CROs) offering proteomics services.
Financials
Chart & Info
Price Chart
Nautilus Biotechnology, Inc. (NAUT) stock price: $1.89 (-0.02, -1.05%)
Why Bull
- •Nautilus recently reported positive advancements in their protein analysis technology, which has garnered significant attention from the biotech community.
- •Insider buying activity has increased, indicating that executives are confident in the company's future prospects and potential breakthroughs.
- •Social sentiment has shifted positively, with discussions around Nautilus's innovative approach gaining traction on platforms like Twitter and Reddit.
- •Partnerships with leading research institutions suggest growing recognition and validation of Nautilus's technology in the scientific community.
Why Bear
- •Concerns persist regarding the scalability of Nautilus's technology, with some investors questioning whether it can meet market demand effectively.
- •Recent market volatility has led to increased skepticism, with bearish sentiment emerging from traders worried about broader economic impacts on biotech stocks.
- •There have been mixed reviews from analysts about the company's long-term growth potential, which has created uncertainty among investors.
- •Community discussions include cautionary tales from past biotech hype cycles, reminding traders of the risks associated with early-stage companies.
Latest News
-
3 Penny Stocks With Market Caps Over $50M To Watch
Simply Wall St. · Feb 6, 2026
-
Earnings Scheduled For October 28, 2025
benzinga · Oct 28, 2025
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Oct 15, 2025
-
Earnings Scheduled For April 29, 2025
benzinga · Apr 29, 2025
Technical Analysis
Rationale
AI-generated technical analysis for NAUT including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Nautilus Biotechnology, Inc. (NAUT) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for NAUT.
Make a Prediction
Set your price target for Nautilus Biotechnology, Inc. (NAUT), choose a timeframe, and track your prediction accuracy.
Current price: $1.89
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NAUT.
Price Targets
Wall Street price target analysis for NAUT.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates NAUT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Nautilus Biotechnology, Inc. do?
Nautilus Biotechnology is a development-stage life sciences company focused on revolutionizing proteomics. They are developing the Nautilus Platform, an end-to-end solution comprised of instruments, consumables, and software analysis, designed to quantify and unlock the complexity of the proteome. The platform aims to provide researchers with unprecedented insights into biological processes and disease mechanisms, potentially accelerating drug discovery, improving diagnostics, and advancing personalized medicine. Currently, Nautilus is focused on the continued development and validation of its platform, working towards commercialization and widespread adoption within the research community.
Is NAUT stock a good buy?
NAUT stock presents a high-risk, high-reward investment opportunity. As a development-stage company, Nautilus has no commercial products and is currently operating at a loss (P/E of -4.08). However, the potential of the Nautilus Platform to revolutionize proteomics could drive significant growth if successfully validated and commercialized. Investors should carefully consider the company's cash burn rate, competition, and regulatory risks before investing. A positive outlook hinges on successful platform validation, strategic partnerships, and market adoption, which could lead to substantial returns.
What are the main risks for NAUT?
The primary risks for Nautilus Biotechnology include the failure to successfully validate and commercialize the Nautilus Platform, competition from established proteomics companies, and the potential for technological advancements to render their platform obsolete. Additionally, the company faces financial risks associated with its high cash burn rate and the need for additional financing. Regulatory hurdles for diagnostic applications also pose a risk. Investors should be aware of these challenges and carefully assess the company's ability to overcome them before investing.
Is NAUT a good stock to buy?
Whether NAUT is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the NAUT MoonshotScore?
The MoonshotScore for NAUT is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is NAUT data updated?
NAUT stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NAUT is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for NAUT?
Growth catalysts for Nautilus Biotechnology, Inc. (NAUT) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Nautilus Biotechnology, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are NAUT's main competitors?
Nautilus Biotechnology, Inc. (NAUT) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NAUT has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about NAUT?
Wall Street analyst coverage for NAUT includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is NAUT's market cap?
Market capitalization (market cap) for NAUT is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NAUT's current market cap alongside enterprise value and other valuation metrics.
How has NAUT stock performed recently?
NAUT's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NAUT's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in NAUT?
Key risk categories for NAUT include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NAUT's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling NAUT?
Insider trading activity for NAUT tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is NAUT a good stock for beginners?
Nautilus Biotechnology, Inc. (NAUT) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is NAUT for first-time investors?
Every stock carries risk, including Nautilus Biotechnology, Inc. (NAUT). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NAUT.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Nautilus Biotechnology is a development stage company, and its future success is dependent on the successful development and commercialization of its platform.